Your best medicine news resource
Jun 30th 2008Drug InformationIrritable-Bowel Syndrome
Persons with irritable bowel syndrome (IBS) can relieve their symptoms as effectively by following a self-administered, at-home cognitive behavioral program as they can by undergoing a 10-week in-office program administered by a trained therapist, a new pilot study has shown.
More: continued here
Jun 19th 2008Drug InformationIrritable-Bowel Syndrome
Hospitals with higher annual volumes of patients with inflammatory bowel disease (IBD) who undergo surgery have lower in-hospital mortality rates than hospitals with lower volumes of IBD patients, according to a new study by researchers at the Medical College of Wisconsin in Milwaukee.The study also found a trend toward shorter post-operative hospital stays for patients who undergo surgery for Crohn’s Disease, a form of IBD, at high-volume centers.
More: continued here
Jun 1st 2008Drug InformationIrritable-Bowel Syndrome
Tioga Pharmaceuticals, Inc. announced the results of a recent Phase 2b study of its oral kappa opioid receptor agonist, asimadoline, which demonstrated statistically significant results in the treatment of Irritable Bowel Syndrome (IBS).
More: continued here
May 22nd 2008Drug InformationIrritable-Bowel Syndrome
Dynogen Pharmaceuticals, Inc. announced the presentation of positive results from its Phase 2a clinical trial for DDP733 (pumosetrag) as a treatment for irritable bowel syndrome with constipation (IBS-c) at the Digestive Disease Week 2008 (DDW) scientific meeting.
More: continued here
May 22nd 2008Drug InformationIrritable-Bowel Syndrome
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced findings from two analyses of the Phase IIb clinical trial of rifaximin, its non-absorbed, gut-selective antibiotic for the treatment of patients with diarrhea-associated irritable bowel syndrome (d-IBS).
More: continued here
May 15th 2008Drug InformationIrritable-Bowel Syndrome
Sucampo Pharmaceuticals, Inc., (NASDAQ: SCMP, Sucampo Pharmaceuticals) and Takeda Pharmaceutical Company Limited (TSE: 4502, Takeda) and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced that the U.S.
More: continued here
May 15th 2008Drug InformationIrritable-Bowel Syndrome
invivodata inc., the industry leader in electronic patient reported outcomes (ePRO) solutions and services for global clinical research, announced that its ePRO solutions - DiaryPROŽ and SitePROŽ- captured primary efficacy data that supported the recent U.S. Food and Drug Administration’s (FDA) supplemental approval of Sucampo Pharmaceutical Inc.
More: continued here
May 15th 2008Drug InformationIrritable-Bowel Syndrome
Researchers at Mattel Children’s Hospital UCLA have found that low-dose antidepressant therapy can significantly improve the overall quality of life for adolescents suffering from irritable bowel syndrome, or IBS.The syndrome affects 6 percent of middle school students and 14 percent of high school kids in the United States.
More: continued here
May 15th 2008Drug InformationIrritable-Bowel Syndrome
The U.S. Food and Drug Administration approved Amitiza (lubiprostone) for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adult women aged 18 and over. There is currently no prescription drug therapy for IBS-C. With this approval, Amitiza becomes the only FDA-approved medical treatment for IBS-C available in the United States. Irritable bowel syndrome is a disorder characterized by cramping, abdominal pain, bloating, constipation, and diarrhea.
More: continued here
Apr 11th 2008Drug InformationIrritable-Bowel Syndrome
Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4) announced that through its wholly-owned subsidiary, Synergy Pharmaceuticals, Inc. it filed an IND on April 2, 2008 with the FDA for SP-304 (also called Guanilib) for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome. SP-304 is an analog of uroguanylin, a natural hormone produced in the gastro-intestinal (GI) tract that is a key regulator of intestinal function.
More: continued here
Your best medicine news resource
